BioCentury
ARTICLE | Company News

Idera, Merck KGaA deal

December 5, 2011 8:00 AM UTC

Idera regained rights to cancer product IMO-2055 following the termination of a 2007 deal with Merck. In July, Idera said Merck would not conduct further development of IMO-2055 after an increased in...